ReviewJournal of clinical medicine2021
A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis.International journal of women's health · 2024Trial
- Still's disease in pregnancy complicated by anakinra-related hepatotoxicity and rescued by intravenous immunoglobulin: a case-based review.Rheumatology international · 2026Review
- Article
- Atypical Femoral Fractures Induced by Anti-Resorptive Medications.Current osteoporosis reports · 2026Review
- Evidence for Maternal Autoantibodies in the Pathogenesis of Preterm Birth.medRxiv : the preprint server for health sciences · 2025Article
- Special Issue "Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies".International journal of molecular sciences · 2025Article
- Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS).Rheumatology (Oxford, England) · 2025Article
- Placental Inflammation in Preterm Premature Rupture of Membranes and Risk of Neurodevelopmental Disorders.Cells · 2025Review
- Anakinra during pregnancy and lactation for corticosteroid-dependant colchicine-resistant recurrent pericarditis in a patient with neutralizing anti-interleukin-1 receptor antagonist antibodies: a case report.European heart journal. Case reports · 2025Article
- N,N-dimethylacetamide blocks inflammation-induced preterm birth and remediates maternal systemic immune responses.Scientific reports · 2025Article
- N,N-dimethylacetamide blocks inflammation-induced preterm birth and remediates maternal systemic immune responses.bioRxiv : the preprint server for biology · 2025Article
- Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology.Nature communications · 2024Article
- IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group BInternational journal of molecular sciences · 2024Article
- Novel Treatments in Refractory Recurrent Pericarditis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis.Life (Basel, Switzerland) · 2024Review
- IL-1 and TNF mediates IL-6 signaling at the maternal-fetal interface during intrauterine inflammation.Frontiers in immunology · 2024Article
- Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study.Therapeutic advances in hematology · 2024Article
- Pericarditis Management in Individuals Contemplating Pregnancy, Currently Pregnant, or Breastfeeding.Current cardiology reports · 2023Review
- Article
- Sex-Specific Dysconnective Brain Injuries and Neuropsychiatric Conditions such as Autism Spectrum Disorder Caused by Group BInternational journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
Blockade of the interleukin-1 (IL-1) pathway has been used therapeutically in several inflammatory diseases including arthritis and cryopyrin-associated periodic syndrome (CAPS). These conditions frequently affect women of childbearing age and continued usage of IL-1 specific treatments throughout pregnancy has been reported. IL-1 is involved in pregnancy complications and its blockade could have therapeutic potential. We systematically reviewed all reported cases of IL-1 blockade in human pregnancy to assess safety and perinatal outcomes. We searched several databases to find reports of specific blockade of the IL-1 pathway at any stage of pregnancy, excluding broad spectrum or non-specific anti-inflammatory intervention. Our literature search generated 2439 references of which 22 studies included, following extensive review. From these, 88 different pregnancies were assessed. Most (64.8%) resulted in healthy term deliveries without any obstetrical/neonatal complications. Including pregnancy exposed to Anakinra or Canakinumab, 12 (15.0%) resulted in preterm birth and one stillbirth occurred. Regarding neonatal complications, 2 cases of renal agenesis (2.5%) were observed, and 6 infants were diagnosed with CAPS (7.5%). In conclusion, this systematic review describes that IL-1 blockade during pregnancy is not associated with increased adverse perinatal outcomes, considering that treated women all presented an inflammatory disease associated with elevated risk of pregnancy complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.